Globus Medical, Inc. $GMED Stock: Stephens Investment Management Group LLC Boosts Stake

Stephens Investment Management Group LLC lifted its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 734,180 shares of the medical device company’s stock after acquiring an additional 10,729 shares during the period. Stephens Investment Management Group LLC owned 0.55% of Globus Medical worth $54,990,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of GMED. Voya Investment Management LLC raised its position in Globus Medical by 12.5% in the 3rd quarter. Voya Investment Management LLC now owns 48,580 shares of the medical device company’s stock worth $3,639,000 after purchasing an additional 5,406 shares during the period. Public Sector Pension Investment Board raised its holdings in shares of Globus Medical by 329.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 253,189 shares of the medical device company’s stock valued at $19,366,000 after purchasing an additional 194,296 shares in the last quarter. Global Retirement Partners LLC boosted its position in Globus Medical by 24.6% during the 3rd quarter. Global Retirement Partners LLC now owns 8,214 shares of the medical device company’s stock valued at $615,000 after acquiring an additional 1,623 shares in the last quarter. South Dakota Investment Council lifted its position in shares of Globus Medical by 11.5% during the third quarter. South Dakota Investment Council now owns 48,621 shares of the medical device company’s stock valued at $3,642,000 after buying an additional 5,000 shares during the last quarter. Finally, Cibc World Market Inc. boosted its stake in Globus Medical by 52.4% in the third quarter. Cibc World Market Inc. now owns 37,082 shares of the medical device company’s stock valued at $2,777,000 after acquiring an additional 12,756 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of Globus Medical stock opened at $70.63 on Thursday. Globus Medical, Inc. has a fifty-two week low of $69.02 and a fifty-two week high of $101.40. The firm has a 50-day simple moving average of $76.23 and a two-hundred day simple moving average of $82.40. The company has a market cap of $9.36 billion, a P/E ratio of 14.08, a price-to-earnings-growth ratio of 1.08 and a beta of 0.98.

Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. The company had revenue of $763.72 million for the quarter, compared to the consensus estimate of $792.39 million. During the same quarter in the prior year, the business posted $1.18 earnings per share. Globus Medical’s revenue for the quarter was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities research analysts forecast that Globus Medical, Inc. will post 4.98 EPS for the current year.

Insider Activity at Globus Medical

In other news, Director James R. Tobin sold 41,666 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the transaction, the director owned 15,000 shares in the company, valued at $1,127,400. This trade represents a 73.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ann Rhoads sold 5,000 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director directly owned 35,384 shares of the company’s stock, valued at approximately $3,007,640. This represents a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 76,666 shares of company stock valued at $5,794,017. 18.38% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages recently commented on GMED. Truist Financial decreased their price objective on shares of Globus Medical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, November 9th. Needham & Company LLC cut their price objective on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, November 6th. BMO Capital Markets downgraded Globus Medical from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $94.00 to $78.00 in a report on Friday, November 6th. Zacks Research downgraded Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, November 9th. Finally, BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $96.08.

Get Our Latest Analysis on GMED

Globus Medical Profile

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Featured Stories

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.